Rationale and design of the REPEAT study: A phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 899-904

  Jensen, Donald M ^a   Marcellin, Patrick ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BEAUJON HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Combination therapy; Non responders; Peginterferon alfa 2a (40 kDa); Peginterferon alfa 2b (12 kDa); Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; REBETRON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RESEARCH DESIGN; RIBAVIRIN; RNA, VIRAL; SAMPLE SIZE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 23944505242     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00003     Document Type: Article

References (13)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123:2082-2099.
2. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52:1784-1787.
3. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
4. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189:964-970.
5. Layden JE, Layden TJ. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 2002; 35:967-970.
6. Diago M, Romero-Gomez M, Crespo J, Olveira A, Perez R, Barcena R, et al. Peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high-dose induction pilot trial [Abstract]. Hepatology 2004;40 (suppl 1):389A.
7. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, et al. Sustained virological response after prolonged treatment with peginterferon alfa-2a (40 KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: TeraVIC-4 study [Abstract]. J Hepatol 2004; 40 (suppl 1):150.
8. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-KD) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
11. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
12. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40:539-551.
13. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20:825-830.